KFAS
SLDB icon

Keating Financial Advisory Services’s Solid Biosciences SLDB Stock Holding History

Keating Financial Advisory Services’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330 Hold
33
– – ﹤0.01% 2391
2026
Q1 		$238 Buy
+33
New +$212 ﹤0.01% 2357

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Keating Financial Advisory Services's SLDB Position: Q2 2026 in Review

Keating Financial Advisory Services held its Solid Biosciences (SLDB) position steady in Q2 2026 at 33 shares worth $330. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

Keating Financial Advisory Services first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Keating Financial Advisory Services held 33 shares of Solid Biosciences worth $330 as of Q2 2026.
  • Keating Financial Advisory Services left its Solid Biosciences share count unchanged in Q2 2026.
  • Solid Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2391 holding.
  • Keating Financial Advisory Services first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.